Graft Versus Host Disease

Stem cells from bone marrow and cord blood are being investigated as a possible treatments for GvHD. Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

tagged as Graft Versus Host Disease

  • Mesenchymal Stromal Cells for Acute Graft Versus Host Disease Location: Australia
    Overview: This trial is investigating the possible beneficial effect of mesenchymal stem cell transplantation in acute graft versus host reaction following bone marrow transplantation or donor lymphocyte cell therapy. The study is being undertaken at the Royal Perth Hospital in Western Australia where patients with newly diagnosed, untreated grade 2-4, acute graft versus host disease will be randomly assigned to control and treatment arms of the study. Those in the control group will receive standard treatment (methylprednisolone intravenously). Those in the treatment group will receive standard treatment plus donated mesenchymal stem cells intravenously. Participants will be assessed for complications and any changes in clinical condition. The trial plans to enrol 66 patients by December 2015 and to be completed by December 2016.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • A phase 1 Multicentre Open Label Dose-Escalation Study of Unrelated, Major Histocompatibility-unmatched Mesenchymal Stem Cells for the Treatment of Steroid Refractory Acute Graft Versus Host Disease in Recipients of Allogeneic Heamatopoietic Stem Cell Transplants Location: Australia
    Overview: This trial aims to evaluate the effect of the transplantation of unmatched bone marrow derived mesenchymal stem cells in the treatment of acute graft versus host disease occurring as a result of a previous donated haematopoietic stem cell transplant. The study is being conducted at the Mater Medical Research Institute and Mater Health in Brisbane and is expected to enrol nine subjects. All participants will receive donated, unmatched, bone marrow derived mesenchymal stem cells and one of three different, escalating doses. Participants will be monitored for complications and assessed for changes in their clinical condition.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Phase II Study of Myeloablative Allogeneic Transplantation Using G-CSF Mobilised Peripheral Blood Stem Cells Location: Australia
    Overview: This trial is designed to evaluate the use of stem cells from a matched sibling in reducing the incidence of graft versus host disease (GVHD) in the treatment of haematological malignancy.The trial is being conducted by the Royal Brisbane and Women's Hospital in conjunction with the Queensland Institute of Medical Research. The trial started in June 2004 and proposes to enrol 47 patients with a haematological malignancy that requires chemotherapy and bone marrow transplant. Participants require a sibling with an identical HLA match as a donor for this trial. Donors will receive an injection of pegylated GCSF to release bone marrow stem cells into the circulation. The stem cells will be isolated from the donor's blood and provided to the trial participant once they have received their chemotherapy The patient will then be monitored for complications including for acute GVHD.
    Link to Clinical Registry
    Trial Design: Observational Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells